Surface Oncology Inc SURF:NASDAQ

Last Price$1.80Cboe Real-Time Last Sale as of 1:01PM ET 8/08/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.01(0.84%)
Bid (Size)$1.79 (391)
Ask (Size)$1.80 (500)
Day Low / High$1.79 - 1.82
Volume407.3 K

View Biotechnology IndustryPeer Comparison as of 08/08/2022


Surface Oncology Inc ( NASDAQ )

Price: $1.80
Change: +0.01 (0.84%)
Volume: 407.3 K
1:01PM ET 8/08/2022

Leap Therapeutics Inc ( NASDAQ )

Price: $1.15
Change: -0.01 (0.86%)
Volume: 161.4 K
12:52PM ET 8/08/2022

aTyr Pharma Inc ( NASDAQ )

Price: $3.64
Change: +0.03 (0.83%)
Volume: 79.5 K
12:49PM ET 8/08/2022

Aspira Women's Health Inc ( NASDAQ )

Price: $1.05
Change: +0.11 (11.70%)
Volume: 166.8 K
11:05AM ET 8/08/2022

Dare Bioscience Inc ( NASDAQ )

Price: $1.23
Change: -0.02 (1.60%)
Volume: 359.8 K
1:02PM ET 8/08/2022

Read more news Recent News

--HC Wainwright Adjusts Price Target on Surface Oncology to $8.50 From $10, Reiterates Buy Rating
6:50AM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Wedbush Cuts Price Target on Surface Oncology to $12 From $14, Citing 'Future Financing Assumptions,' Keeps Outperform Rating
4:43AM ET 5/12/2022 MT Newswires

Surface Oncology (SURF) has an average rating of buy and price targets ranging from $10 to $14, according to analysts polled by Capital IQ. (MT Newswires...

Surface Oncology Starts Two Mid-Stage Trials of Experimental Cancer Drug
8:13AM ET 4/14/2022 MT Newswires

Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a...

Surface Oncology Secures $30 Million Milestone Payment After First Patient Dosed in Study; Shares Rise
8:00AM ET 3/31/2022 MT Newswires

Surface Oncology (SURF) said Thursday that it has received a $30 million milestone payment as GlaxoSmithKline (GSK) has dosed the first patient in a phase...

Company Profile

Business DescriptionSurface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address50 Hampshire Street
Cambridge, Massachusetts 02139
Number of Employees76
Recent SEC Filing08/05/20224
President, Chief Executive Officer & DirectorRobert W. Ross
Chief Financial OfficerJessica Fees
Chief Scientific OfficerVito J. Palombella
Chief Medical OfficerAlison M. O'Neill

Company Highlights

Price Open$1.79
Previous Close$1.78
52 Week Range$1.37 - 8.38
Market Capitalization$104.2 M
Shares Outstanding58.0 M
SectorHealth Technology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.30
Beta vs. S&P 500N/A
Revenue$59.4 M
Net Profit Margin-206.10%
Return on Equity-48.17%

Analyst Ratings as of 05/14/2021

Consensus RecommendationConsensus Icon
Powered by Factset